Why did Nnenna John start Burna AI?

Years of conversations with oncologists, research coordinators, and pharmacovigilance leaders surfaced a single architectural gap: oncology adverse event grading and attribution sit at the chokepoint of drug development, the inter-rater variability is well-published, the manual grading burden is concentrated, and no existing platform helps the investigator make the attribution decision at the point of clinical encounter. The Airbnb platform engineering experience is the foundation: every cancer trial deserves architecture that can defend its safety data, and citation-bound design is the only honest way to deploy LLMs into regulated clinical workflows.